Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Reinhorn

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Oncology|August 23, 2021
Novel and Promising Systemic Treatment Approaches in MesotheliomaElizabeth Dudnik, Daniel Reinhorn, Liran Holtzman
Cancer|April 2, 2025
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategiesDaniel Reinhorn, Mor Moskovitz, William D Tap, et al.
Breast (Edinburgh, Scotland)|June 23, 2021
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysisDaniel Reinhorn, Raz Mutai, Rinat Yerushalmi, et al.
Thoracic Cancer|July 15, 2025
Planning Target Volume and Nodal Status Predict Clinical Outcomes After Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung CancerOri Aslan, Johnathan Arnon, Itamar Averbuch, et al.
Breast Cancer Research and Treatment|June 4, 2020
Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancerDaniel Reinhorn, Rinat Yerushalmi, Assaf Moore, et al.
Immunotherapy|March 20, 2020
Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancerDaniel Reinhorn, Oded Jacobi, Oded Icht, et al.
The Oncologist|February 3, 2019
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell CarcinomaDaniel Reinhorn, Michal Sarfaty, Moshe Leshno, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|December 2, 2025
Head and neck sarcomas across two decades: a retrospective study of clinicopathologic patterns and oncologic outcomesDean Dudkiewicz, Nir Tsur, Shahar Barami, et al.
Cancer Medicine|May 7, 2020
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancerDaniel A Goldstein, Chen Mayer, Tzippy Shochat, et al.
Oncotargets and Therapy|April 6, 2026
High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary CentersOded Icht, Bilal Krayim, Mor Moskovitz, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Oncology|August 23, 2021
Novel and Promising Systemic Treatment Approaches in MesotheliomaElizabeth Dudnik, Daniel Reinhorn, Liran Holtzman
Cancer|April 2, 2025
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategiesDaniel Reinhorn, Mor Moskovitz, William D Tap, et al.
Breast (Edinburgh, Scotland)|June 23, 2021
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysisDaniel Reinhorn, Raz Mutai, Rinat Yerushalmi, et al.
Thoracic Cancer|July 15, 2025
Planning Target Volume and Nodal Status Predict Clinical Outcomes After Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung CancerOri Aslan, Johnathan Arnon, Itamar Averbuch, et al.
Breast Cancer Research and Treatment|June 4, 2020
Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancerDaniel Reinhorn, Rinat Yerushalmi, Assaf Moore, et al.
Immunotherapy|March 20, 2020
Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancerDaniel Reinhorn, Oded Jacobi, Oded Icht, et al.
The Oncologist|February 3, 2019
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell CarcinomaDaniel Reinhorn, Michal Sarfaty, Moshe Leshno, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|December 2, 2025
Head and neck sarcomas across two decades: a retrospective study of clinicopathologic patterns and oncologic outcomesDean Dudkiewicz, Nir Tsur, Shahar Barami, et al.
Cancer Medicine|May 7, 2020
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancerDaniel A Goldstein, Chen Mayer, Tzippy Shochat, et al.
Oncotargets and Therapy|April 6, 2026
High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary CentersOded Icht, Bilal Krayim, Mor Moskovitz, et al.
Pageof 3